Results 201 to 210 of about 156,133 (264)

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

Expanding the OMOP common data model to support extracorporeal life support research. [PDF]

open access: yesJAMIA Open
Rieder C   +16 more
europepmc   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane   +19 more
wiley   +1 more source

Retraction Note: LncRNA CCAT1 facilitates the progression of gastric cancer via PTBP1-mediated glycolysis enhancement. [PDF]

open access: yesJ Exp Clin Cancer Res
Zhang C   +8 more
europepmc   +1 more source

A dataset of preclinical tooth preparation images. [PDF]

open access: yesData Brief
Fraiwan M, Al Fodeh R, Shamiyah D.
europepmc   +1 more source

Nine quick tips for software containerization. [PDF]

open access: yesPLoS Comput Biol
Moreau D, Wiebels K.
europepmc   +1 more source

Home - About - Disclaimer - Privacy